peptideInjectableNot FDA-approvedResearch chemicalStudied historically as a diagnostic and pediatric growth-hormone-deficiency agent; not currently marketed as an approved US drugSold today primarily as a research chemical
GHRH (1-29)Benefits, Dosage & Interactions
Also known as: GRF
GHRH (1-29), also known as Growth Hormone-Releasing Hormone (1-29) or Sermorelin, is a synthetic peptide fragment representing the first 29 amino acids of endogenous human Growth Hormone-Releasing Hormone (GHRH). Research on GHRH (1-29) focuses on muscle and strength. GHRH (1-29) is administered by injection rather than orally.
How much GHRH (1-29) do people take?
Pediatric growth-hormone-deficiency and short-stature trials used low-dose bolus or continuous subcutaneous GHRH(1-29) in the low microgram-per-kilogram range. Route reported: Subcutaneous, given as bolus injections or via continuous subcutaneous infusion pump in the cited trials. Frequency reported: Multiple daily bolus doses or continuous infusion, depending on the protocol. These are amounts documented in the cited studies and labels for GHRH (1-29) — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Moderate — One published human randomized trial; results not yet replicated.
Evidence strengthModerate · 3/4
PreclinicalStrong human evidence
One published human randomized trial; results not yet replicated.
Plasma half-life
Reported as only a few minutes in circulation after injection in these studies
Typical timing
in the evening
Default unit
mcg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Pediatric growth-hormone-deficiency and short-stature trials used low-dose bolus or continuous subcutaneous GHRH(1-29) in the low microgram-per-kilogram range[1][2][3][4]
- Route studied
- Subcutaneous, given as bolus injections or via continuous subcutaneous infusion pump in the cited trials[1][2][3][4]
Reported for GHRH (1-29) in the cited sources. Published ranges are not dosing advice.
Mixing GHRH (1-29): bacteriostatic water and syringe units
The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 5 mg vial and a 250 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.
| Bacteriostatic water added | Resulting strength | 250 mcg draws to |
|---|---|---|
| 1 mL | 5 mg/mL | 5 units |
| 2 mL | 2.5 mg/mL | 10 units |
| 3 mL | 1.67 mg/mL | 15 units |
Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.
Storage and stability
- Before mixing
- Sealed and still as a dry powder, GHRH (1-29) vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
- After mixing
- Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
- When to throw it out
- A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.
Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.
References & evidence
Documents the GHRH (1-29) entry is written from. Each number matches an inline marker above.
- [1]The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients with longstanding post-irradiation GH insufficiencyAchermann JC, Brook CG, Hindmarsh PC · European Journal of Endocrinology · 2000 · Peer-reviewed · PMID 10754477
- [2]Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocityKirk JM, Trainer PJ, Majrowski WH, Murphy J, Savage MO, Besser GM · Clinical Endocrinology · 1994 · Peer-reviewed · PMID 7955460
- [3]Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing childrenBrain CE, Hindmarsh PC, Brook CG · Clinical Endocrinology · 1990 · Peer-reviewed · PMID 2140733
- [4]Priming with GHRH (1-29) NH2: an aid in differential diagnosis between hypothalamic and pituitary deficienciesBueno G, Bueno M, Garagorri JM, Juste G, Rejas J, Alvarez I · Journal of Pediatric Endocrinology · 1994 · Peer-reviewed · PMID 7735368
References & Evidence
Sources on this page that document GHRH (1-29) dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is GHRH (1-29) studied for?
What is GHRH (1-29)?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
GHRH (1-29), also known as Growth Hormone-Releasing Hormone (1-29) or Sermorelin, is a synthetic peptide fragment representing the first 29 amino acids of endogenous human Growth Hormone-Releasing Hormone (GHRH). It is classified as a secretagogue because it stimulates the pituitary gland to release its own growth hormone (GH) in a pulsatile, natural manner. Unlike direct administration of synthetic growth hormone, GHRH (1-29) encourages the body's natural physiological production and release of GH, which in turn can lead to increased levels of insulin-like growth factor-1 (IGF-1). The regulation of GH and IGF-1 is critical for many physiological processes, including body composition, metabolism, and cellular repair. Due to its short half-life and natural mode of action, GHRH (1-29) has been investigated for various applications, particularly those related to growth hormone deficiency, muscle development, and recovery processes. It is typically administered via subcutaneous injection.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
What does the research say about GHRH (1-29)?
Tap a section to expand.
GHRH (1-29) functions by binding to specific Growth Hormone-Releasing Hormone Receptors (GHRH-Rs) located on somatotroph cells within the anterior pituitary gland. Upon binding, GHRH (1-29) initiates a signaling cascade that primarily involves the activation of adenylyl cyclase, leading to an increase in intracellular cyclic AMP (cAMP) levels. Elevated cAMP then triggers a series of events culminating in the synthesis and pulsatile release of stored growth hormone (GH) from the somatotrophs into the bloodstream. This mechanism mimics the natural physiological process by which the hypothalamus regulates GH secretion. The released GH then acts on various target tissues throughout the body, either directly or indirectly through the stimulation of Insulin-like Growth Factor-1 (IGF-1) production, primarily in the liver. IGF-1 mediates many of the anabolic and growth-promoting effects attributed to GH, including protein synthesis, cell proliferation, and tissue repair. The pulsatile nature of GH release induced by GHRH (1-29) is considered to be more physiological than continuous GH administration, potentially reducing the risk of desensitization or negative feedback alterations over time. (DrugBank, PubChem)
Source for this section: Sources for How does GHRH (1-29) work?: Jumps to this entry in the sources and references list at the end of the page.
The benefits associated with GHRH (1-29) largely stem from its ability to stimulate the endogenous release of growth hormone (GH) and, subsequently, insulin-like growth factor-1 (IGF-1). These effects can contribute to:
* **Muscle Growth (Anabolism):** Increased GH and IGF-1 levels are known to promote protein synthesis and reduce protein degradation, which can support the development and maintenance of lean muscle mass. This makes it an area of interest for individuals looking to enhance their muscularity and strength. (DrugBank, PubMed citations for related research)
* **Improved Recovery:** Enhanced cellular repair and regeneration, mediated by GH and IGF-1, can contribute to faster recovery from physical exertion, injury, or strenuous exercise. This might involve quicker resolution of muscle soreness and restoration of tissue integrity. (PubMed citations for related research)
* **Body Composition Alterations:** GH has roles in fat metabolism, promoting lipolysis (fat breakdown) and potentially contributing to a reduction in adipose tissue while supporting lean mass. This can lead to a more favorable body composition. (DrugBank, PubMed citations for related research)
* **Bone Density Support:** GH and IGF-1 play roles in bone remodeling and mineralization. While not a primary indication, sustained healthy levels could contribute to bone health. (PubMed citations for related research)
* **Skin Health and Anti-Aging:** Some anecdotal evidence and preliminary research suggest that optimized GH levels might improve skin elasticity and overall vitality, though this is less robustly established. (PubMed citations for related research)
It's important to note that while these benefits are theoretically plausible based on the known actions of GH and IGF-1, the extent and significance of these effects in healthy individuals, particularly in the context of GHRH (1-29) use, can vary and are a subject of ongoing research.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Research on GHRH (1-29), also known as Sermorelin, has primarily focused on its efficacy in diagnosing and treating growth hormone deficiency (GHD) in children and adults. Clinical trials have demonstrated its ability to stimulate a dose-dependent increase in growth hormone production in individuals with intact pituitary function. (NIH ODS - DailyMed, FDA label for Sermorelin). For example, studies assessing GHRH (1-29) in children with GHD showed improvements in growth velocity. (FDA label for Sermorelin).
Beyond GHD, investigations into GHRH (1-29)'s potential for muscle growth and recovery in healthy adults are ongoing. While the underlying physiological mechanisms (GH and IGF-1 stimulation) support these theoretical benefits, direct, large-scale clinical trials specifically proving significant muscle hypertrophy or accelerated recovery in *healthy* individuals using GHRH (1-29) are less numerous than those for GHD treatment. Much of the evidence regarding muscle anabolism and recovery comes from understanding the broader roles of growth hormone and IGF-1, and from smaller studies or anecdotal reports in athletic populations. (PubChem, PubMed citations for related research on GH/IGF-1 actions).
Regulatory bodies, such as the FDA, have approved related GHRH formulations (e.g., Sermorelin) for specific medical conditions, primarily GHD in children. Its use for enhancing athletic performance or for general anti-aging purposes in healthy adults is not a medically approved indication and is largely off-label.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Side effects associated with GHRH (1-29) are generally mild and localized, though systemic effects can occur. Common localized reactions at the injection site include pain, swelling, redness, and irritation. Systemic side effects, while less frequent, can include:
* Headache
* Flushing of the face
* Dizziness or lightheadedness
* Nausea
* Vomiting
* Dysgeusia (altered taste sensation)
* Pruritus (itching)
* Tightness or pain in the chest
* Somnolence (drowsiness)
More rarely, individuals might experience antibodies to GHRH (1-29) or an increase in anticerebellar antibodies, though the clinical significance of these is often unclear. As it stimulates growth hormone release, it can theoretically lead to some of the side effects associated with excessive GH, such as carpal tunnel syndrome, joint pain, or edema, particularly with prolonged use or in sensitive individuals, though these are typically less pronounced than with exogenous GH administration due to the pulsatile release mechanism. (FDA label for Sermorelin, DrugBank).
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Before using GHRH (1-29), individuals should be aware of several important warnings. It should not be used in individuals with known hypersensitivity to GHRH (1-29) or any of its excipients. Caution is advised in individuals with a history of any endocrine disorders, pituitary tumors, or other serious medical conditions. Because GHRH (1-29) stimulates the body's own GH production, its effects on conditions sensitive to growth hormone levels (e.g., glucose metabolism, thyroid function, existing tumors) should be carefully monitored. Diabetic individuals may require adjustments to their insulin or antidiabetic medication. It is not approved for use in pregnant or breastfeeding women, and its safety in these populations has not been established. Due to its impact on growth hormones, long-term safety data in healthy individuals without GHD is limited, and its use for performance enhancement or anti-aging is not medically sanctioned. Individuals should ensure they are using a legitimate and pure product, as unregulated peptide markets can pose significant risks. (FDA label for Sermorelin, PubChem).
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
GHRH (1-29) is contraindicated in individuals with a known hypersensitivity to GHRH (1-29) or to any of the excipients in the formulation. It is also contraindicated in individuals with active untreated intracranial lesions, particularly pituitary tumors, as the stimulation of growth hormone could potentially exacerbate such conditions. Its use is generally not recommended in patients with closed epiphyses who are no longer growing. Due to its mechanism of action, it is important to consider any pre-existing medical conditions that might be adversely affected by increased growth hormone levels. The safety and efficacy for indications other than those approved by regulatory bodies (e.g., growth hormone deficiency diagnosis/treatment) have not been established. (FDA label for Sermorelin, DrugBank).
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
When considering GHRH (1-29), caution is advised when mixing with certain compounds, particularly those that can influence endocrine function or the hypothalamic-pituitary axis.
* **Glucocorticoids:** Concomitant use of glucocorticoids can inhibit the growth hormone-releasing effects of GHRH (1-29), potentially reducing its efficacy.
* **Somatostatin and Somatostatin Analogs:** Somatostatin naturally inhibits GH release. Therefore, compounds that mimic somatostatin's action or increase its levels can counteract the effects of GHRH (1-29).
* **Compounds Affecting the Pituitary Gland:** Any medications or substances that directly impact pituitary function or other hormonal axes should be used with caution, as they could alter the expected response to GHRH (1-29).
* **Insulin and Oral Hypoglycemic Agents:** Since growth hormone can influence glucose metabolism, individuals on insulin or oral hypoglycemic agents for diabetes may require careful monitoring and potential dose adjustments.
* **Other Growth Hormone Secretagogues:** Combining GHRH (1-29) with other compounds that stimulate GH release (e.g., GHRPs - Growth Hormone Releasing Peptides) is a common practice in research and theoretical discussion, but the combined effects and potential for additive side effects or receptor desensitization need to be considered. The safety and optimal interactions of such combinations are not fully established in clinical settings.
Always consult with a healthcare professional regarding potential interactions, especially with prescription medications or other potent compounds. (FDA label for Sermorelin, DrugBank).
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
GHRH (1-29) has a very short half-life, typically around 12 minutes (0.2 hours). Due to this short half-life and the natural pulsatile release pattern of growth hormone (GH), timing of administration is often considered significant. Many protocols suggest administration approximately 30-60 minutes before bedtime. This timing is chosen to coincide with the body's natural nocturnal GH pulse, potentially maximizing its physiological release and minimizing interference with circadian rhythms. Some protocols may also suggest administration post-workout to support recovery processes, or in the morning. The specific dosage and frequency, which must be determined by a licensed clinician, will influence the overall effect profile. Given that food intake, especially carbohydrates and fats, can suppress growth hormone release, some users prefer to administer GHRH (1-29) on an empty stomach, or at least 1-2 hours after their last meal and 30-60 minutes before any subsequent food intake. However, GHRH (1-29) has been found to be effective whether food is consumed or not, meaning it can be taken with or without food. (DrugBank, PubMed citations for related research).
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for When should you take GHRH (1-29)?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about GHRH (1-29) is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with GHRH (1-29)?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about GHRH (1-29)
GHRH (1-29), also known as Sermorelin, is medically approved for the diagnosis and treatment of growth hormone deficiency (GHD) in children. In other contexts, it is explored for its potential to stimulate natural growth hormone release for muscle growth, improved recovery, and altered body composition.
GHRH (1-29) is typically administered via subcutaneous injection.
GHRH (1-29) has a very short half-life, approximately 12 minutes (0.2 hours) in the bloodstream.
While GHRH (1-29) stimulates natural growth hormone release which can influence muscle anabolism, its use for muscle building in healthy individuals is not an FDA-approved indication. Research is ongoing, and its effectiveness for this purpose in healthy populations compared to those with GHD is a subject of debate and scientific inquiry.
Common side effects include localized injection site reactions (pain, redness, swelling). Other possible side effects include headache, flushing, dizziness, nausea, and changes in taste. More serious side effects are rare but possible due to its impact on growth hormone levels.
Interaction risk for GHRH (1-29) comes from the rest of the stack: other peptides, prescription medicines, hormone therapy and peptides. Because GHRH (1-29) is usually taken in the evening, most avoidable conflicts come from what else lands in that same window. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers GHRH (1-29) with no sign-up.
GHRH (1-29) is typically taken in the evening. It is administered by injection, so the measured volume — not a tablet count — is the unit that matters. Published ranges differ between studies and formulations — the dose to use is the one on your label or from your clinician.
There is no single answer for GHRH (1-29) plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing GHRH (1-29) with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for GHRH (1-29) varies by protocol and formulation, so the label or prescription is what sets it. It is typically taken in the evening. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of GHRH (1-29) depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like GHRH (1-29) the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Pediatric growth-hormone-deficiency and short-stature trials used low-dose bolus or continuous subcutaneous GHRH(1-29) in the low microgram-per-kilogram range. Route reported: Subcutaneous, given as bolus injections or via continuous subcutaneous infusion pump in the cited trials. Frequency reported: Multiple daily bolus doses or continuous infusion, depending on the protocol. These are amounts documented in the cited studies and labels for GHRH (1-29) — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at GHRH (1-29)?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Priming with GHRH (1-29) NH2: an aid in differential diagnosis between hypothalamic and pituitary deficiencies(opens PubMed in a new tab)J Pediatr Endocrinol · 1994 · PMID 7735368 · https://pubmed.ncbi.nlm.nih.gov/7735368/
- 2.Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men(opens PubMed in a new tab)Metabolism · 1997 · PMID 9005976 · https://pubmed.ncbi.nlm.nih.gov/9005976/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 16199244(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/16199244
Verify at
Publisher search links for GHRH (1-29). These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on GHRH (1-29)?
Plain-text summary, safe to quote verbatim:
GHRH (1-29), also known as Growth Hormone-Releasing Hormone (1-29) or Sermorelin, is a synthetic peptide fragment representing the first 29 amino acids of endogenous human Growth Hormone-Releasing Hormone (GHRH). Research on GHRH (1-29) focuses on muscle and strength. GHRH (1-29) is administered by injection rather than orally.
Source: DoseRoutine — https://doseroutine.com/library/ghrh-1-29
GHRH (1-29) cheat sheet
DoseRoutine cheat sheet · Peptide
GHRH (1-29)
GHRH (1-29), also known as Growth Hormone-Releasing Hormone (1-29) or Sermorelin, is a synthetic peptide fragment representing the first 29 amino acids of endogenous human Growth Hormone-Releasing Hormone (GHRH).
Evidence
Moderate
One published human randomized trial; results not yet replicated.
Studied range
Pediatric growth-hormone-deficiency and short-stature trials used low-dose bolus or continuous subcutaneous GHRH(1-29) in the low microgram-per-kilogram range
Route
Subcutaneous, given as bolus injections or via continuous subcutaneous infusion pump in the cited trials
Frequency studied
Multiple daily bolus doses or continuous infusion, depending on the protocol
Half-life
Reported as only a few minutes in circulation after injection in these studies
Timing
in the evening
Not FDA-approvedResearch chemicalStudied historically as a diagnostic and pediatric growth-hormone-deficiency agent; not currently marketed as an approved US drugSold today primarily as a research chemicalMuscle
Key references
- The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients with longstanding post-irradiation GH insufficiency (2000)
- Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity (1994)
- Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children (1990)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/ghrh-1-29
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). GHRH (1-29) — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/ghrh-1-29
What compounds are similar to GHRH (1-29)?
Others in the peptide category or studied for the same goals.
Which goals is GHRH (1-29) used for?
Other compounds studied for the same benefits as GHRH (1-29).
Continue exploring
See every compound DoseRoutine catalogs for these goals.